The US FDA declined to approve Elevar Therapeutics’ liver cancer drug combination, citing deficiencies at a manufacturing site. The company had sought approval for rivoceranib and camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma.
Elevar’s CEO, Dong-Gun Kim, stated that the company will work closely with the FDA to determine the appropriate path forward.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.